59 results about "Arginase" patented technology

Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase:whereinR1 is —NHR1a;R1a is —H or —C(O)CH(R1b)NHR1c; andR1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; orR1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; andR1d is H or —CH3.

Disclosed are compositions containing exosomes loaded with arginase or arginase chimeras for treating hyperammonemia due to arginase deficiency, and methods for treating hyperammonemia by administering compositions containing exosomes loaded with arginase or arginase chimeras.

The present invention relates to a protein arginine methyltransferase-5 (PRMT5) inhibitor and a pharmaceutical use thereof. Specifically, the present invention relates to a compound represented by general formula (I), a preparation method for the compound, a pharmaceutical composition comprising the compound, and a use of the compound as a PRMT5 inhibitor for treating diseases related to PRMT5 activity. The definitions of the groups in general formula (I) are the same as those in the description.

The present invention relates to a protein arginase methyltransferase-5 inhibitor and the medical use thereof. Specifically, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and the use thereof as a PRMT5 (protein arginase methyltransferase-5) inhibitor in the treatment of diseases related to PRMT5 activity. The definition of each group in general formula (I) is the same as defined in the description.

Described are methods for producing recombinant Arginase, such as PEGylated, cobalt-substituted recombinant human Arginase 1. Also described are pharmaceutical compositions comprising such recombinant Arginase, as well as methods of treatment and uses of such recombinant Arginase.

The invention discloses a drug delivery system for metabolism regulation of specific immune cells and a preparation method and application thereof.The drug delivery system is of a double-layer vesicle structure and comprises inner vesicles and outer vesicles, the inner vesicles are polymer vesicles formed by self-assembly of diblock polymers PEI-b-PLA or PEI-b-PLA, and the outer vesicles are polymer vesicles formed by self-assembly of diblock polymers PEI-b-PLA or PEI-b-PLA. The outer wall of the inner-layer vesicle is positively charged and is loaded with a therapeutic gene for immunoregulation of Arginase-1, the surface of the inner-layer vesicle is modified by an antibody targeting an MDSC cell surface marker, and a biguanide therapeutic drug is loaded in the inner-layer vesicle; the outer-layer vesicle is a liposome-like vesicle modified by angiotensin converting enzyme substrate polypeptide-PEG (Polyethylene Glycol) which is disintegrated in a targeted manner. The drug delivery system designed by the invention can effectively avoid influence on immune cells outside a focus, and further performs specific drug delivery and function regulation and control on immune cells such as immune microenvironment MDSC in the focus, so that effective immunotherapy of placental diseases becomes possible.

Described herein are compositions comprising a lanthanide (III) modified fatty acid and methods of treating cancer with the composition. In particular, the application includes a lanthanide (III) modified fatty acid is a 9-R′, 10-R″ tri octadecanoate compound. This lanthanide (III) modified fatty acid can be combined with additional therapeutic agents, such as chemotherapeutic agents, radiopharmaceuticals, hormone therapies, CDK inhibitors, epigenetic modulators, selective estrogen receptor modulators, selective estrogen receptor degraders, aromatase inhibitors, phosphatidyl inositol-3-posphate kinase inhibitors, ATP-adenosine axis-targeting agents, signal transduction inhibitors, RAS signaling inhibitors, PI3K inhibitors, arginase inhibitors, HIF inhibitors, AXL inhibitors, PAK4 inhibitors, immunotherapeutic agents, immune checkpoint inhibitors, and agonists of stimulatory or co-stimulatory immune checkpoints.

To provide use methods of compositions in drug production for inhibiting cancer cells having low asparagine synthetase (ASNS) expression.SOLUTION: The disclosure relates to a use method of a composition comprising an arginine reducing compound and an asparagine reducing compound for preparing a medicament to inhibit a cancer cell, where an arginase being the arginine reducing compound is specifically effective in combination use with an asparaginase being the arginine reducing compound for inhibiting proliferation of cancer cells, in particular, cells having low ASNS expression. Further, the medicament comprises a compound that reduces glutamine concentration such as an aminotransferase inhibitor.SELECTED DRAWING: Figure 1

Disclosed herein include crystalline (S)-2-amino-N-((3R,5R)-8-hydroxy-6-oxo-7-oxa-1-aza-8-boraspiro[4.7]dodecan-3-yl)-3-methylbutyramide of Form D and Form E: Formula (I); (3R,5R)-8-hydroxy-3-((S)-4-isopropyl-2,2-dimethyl-5-oxoimidazolidin-1-yl)-7-oxa-1-aza-8-boraspiro[4.7]dodecan-6-one or a pharmaceutically acceptable salt thereof or Crystal Form 1 thereof: Formula (II); and pharmaceutical compositions and methods of using the same. #imgabs0#

The present invention relates to new polypeptides derived from arginase 2. The present invention also relates to uses of said polypeptides and compositions comprising said polypeptides.

The present disclosure relates to a compound represented by Chemical Formula 1 in the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same can be used favorably for preventing or treating cancer or tumors.

The invention relates to an engineered extracellular vesicle with an anti-inflammatory effect and a preparation method of the engineered extracellular vesicle. The engineered extracellular vesicle comprises an extracellular vesicle, an arginase 1 mutant located in a cavity of the extracellular vesicle, an internal support protein for connecting the arginase 1 mutant with the extracellular vesicle, and an external support protein for connecting the internal support protein with the extracellular vesicle, the arginase 1 mutant comprises an arginase 1 protein and a trimer tag, the C end of the arginase 1 protein is connected with the trimer tag, and the N end of the arginase 1 protein is connected with the C end of an endogenous scaffold protein. The engineered extracellular vesicle disclosed by the invention is high in loading efficiency and good in delivery effect, has multi-target activity and has an enhanced broad-spectrum anti-inflammatory effect.

The invention disclosed herein provides methods and materials useful in gene therapy regimens designed to inhibit myelination abnormalities that occur in the urea cycle disorder arginase deficiency. The underlying cause of the progressive neurological dysfunction that occurs in this disorder has been previously unknown and conventional therapies, at best, only slow the onset of neurological dysfunction. This neurological dysfunction results at least in part from the dysmyelination that occurs in the central nervous system due to the lack of adequate hepatic expression of arginase 1. We have discovered an origin of this neurological dysfunction and, using this information, designed materials and associated methods of gene therapy. The methods and materials disclosed herein can inhibit and essentially prevent neurological dysfunction in a murine model of arginase deficiency.

The present invention relates to novel polypeptides, which are derived from Arginase2. The invention also concerns uses of the polypeptides and compositions comprising the polypeptides.

Disclosed are compositions containing exosomes loaded with arginase or arginase chimeras for treating hyperammonemia due to arginase deficiency, and methods for treating hyperammonemia by administering compositions containing exosomes loaded with arginase or arginase chimeras.

The present disclosure relates to a compound represented by Chemical Formula 1 in the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same can be used favorably for preventing or treating cancer or tumors.

Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase:whereinR1 is —H or —C(O)CH(R1a)NHR1b; andR1a is selected from —H, —(C1-C4) alkyl and CH2OR1c;R1b is —H; or alternatively, R1a and R1b, together with the atom to which they are attached, form a 5-membered heterocyclic ring; andR1c is H or —CH3.

1. A method of treating arginase 1 (ARG1) deficiency (ARG1-D) in a subject, comprising administering pegylarginase to the subject, wherein the pegylarginase is pegylated human arginase 1 that includes a cobalt metal cofactor, and wherein the pegylarginase is administered at a dose of about 0.05 mg / kg to about 0.2 mg / kg weekly.

The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory disease, comprising mesenchymal stem cells expressing PTX-3, TIMP1, and BDNF as an active ingredient. The mesenchymal stem cells expressing PTX-3, TIMP1, BDNF, and / or HLA-A2, according to the present invention, may inhibit an inflammatory response by reducing the expressions of the inflammatory cytokines IL-1b, IL-6, IL-8, and TNF-a, and increasing the expressions of the anti-inflammatory cytokines IL-10 and arginase-1 (ARG-1), and may relieve pain caused by osteoarthritis when administered in an osteoarthritis-induced rat. Thus, the mesenchymal stem cells expressing PTX-3, TIMP1, and BDNF of the present invention may be usefully employed in the prevention, alleviation, or treatment of inflammatory disease, pain, and pain cuased by inflammation.

The present disclosure relates to a compound represented by Chemical Formula 1 in the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same can be used favorably for preventing or treating cancer or tumors.

The present invention relates to a compound represented by chemical formula 1, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof can be effectively used for the prevention or treatment of cancer or tumors. [Chemical formula 1] In chemical formula 1, R is as defined in the specification.

The present invention describes methods for producing recombinant arginase enzymes, such as pegylated cobalt substituted recombinant human arginase 1. Also described are pharmaceutical compositions comprising such recombinant arginases, as well as methods of treatment and uses of such recombinant arginases.

The invention provides a method for producing spermidine comprising the following steps: a1) converting L-arginine to L-ornithine by an arginase; a2) converting L-aspartate to L-4- aspartylphosphate by a kinase; b1) converting the L-ornithine of step a1) to putrescine by a decarboxylase; b2) converting the L-4-aspartylphosphate of step a2) to L-aspartate-4- semialdehyde by a dehydrogenase; c1) converting the putrescine of step b1) and the L- aspartate-4-semialdehyde of step b2) to carboxyspermidine by a dehydrogenase; and c2) converting the carboxyspermidine of step c1) to spermidine by a decarboxylase. Further, the present invention provides a host cell for producing spermidine, and the use of said host cell for producing spermidine.

The present invention relates to novel polypeptides, which are derived from Arginase2. The invention also concerns uses of the polypeptides and compositions comprising the polypeptides.

Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase; wherein R1 is —H or —C(O)CH(R1a)NHR1b; and R1a is selected from —H, —(C1-C4) alkyl and CH2OR1c; R1b is —H; or alternatively, R1a and R1b, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1c is H or —CH3.

The present invention describes methods for producing recombinant arginase enzymes, such as pegylated cobalt substituted recombinant human arginase 1. Also described are pharmaceutical compositions comprising such recombinant arginases, as well as methods of treatment and uses of such recombinant arginases.

The present invention relates to novel polypeptides, which are derived from Arginase 1. The invention also relates to polynucleotides encoding the polypeptides. The invention also relates to compositions comprising the polypeptides and polynucleotides. The invention also concerns uses of the polypeptides, polynucleotides, and compositions.

To provide a therapy of guanidinoacetate methyltransferase (GAMT) deficiency.SOLUTION: A method and a composition for treating GAMT deficiency or guanidinoacetic acid (GAA) toxicity in a subject include administration of arginine depleted enzyme. A therapeutic preparation can contain arginase, arginine deiminase or a combination thereof, and other compounds if needed, and can be adapted for intravenous or subcutaneous administration to a subject.SELECTED DRAWING: None

Methods for producing recombinant arginase, such as PEGylated and cobalt-substituted recombinant human arginase 1, are described. Pharmaceutical compositions containing this recombinant arginase, as well as methods of processing and uses thereof, are also described.

The application discloses arginase 2 inhibiting peptides and application thereof in wound healing. The arginase 2 inhibiting peptide has an amino acid sequence as shown in SEQ ID No. 1 or a mutant sequence thereof. It is found through research of the application at a cell level and in a mouse skin wound model that MUT4-short peptide and MUT5-short peptide can effectively improve the viability and migration ability of keratinocytes under high-sugar conditions in vitro and in a metabolic abnormality model in vivo, reduce the intracellular reactive oxygen level, and promote the repair process of skin wounds, wherein the MUT4-short peptide shows more significant in promoting the recovery of cell functions and accelerating wound healing, and has a good application prospect in promoting skin wound healing, especially in the treatment of difficult-to-heal wounds related to metabolic diseases such as diabetes.